Table 1 Clinicopathologic characteristics of 1974 patients with primary gastric cancer according to the FGFR2b overexpression
Variable | FGFR2b by IHC | |||
|---|---|---|---|---|
No expression (n=1901,%) | Overexpression (n=73, %) | P value | ||
Age (years) | 0.73 | |||
<60 | 1186 (62.4) | 47 (64.4) | ||
≥60 | 715 (37.6) | 26 (35.6) | ||
Sex | 0.492 | |||
Male | 1246 (65.5) | 45 (61.6) | ||
Female | 655 (34.5) | 28 (38.4) | ||
WHO type | <0.001a | |||
W/D | 36 (1.9) | 1 (1.4) | ||
M/D | 460 (24.2) | 4 (5.5) | ||
P/D | 855 (45.0) | 43 (58.9) | ||
Signet ring cell | 418 (22.0) | 21 (28.8) | ||
Mucinous | 71 (3.7) | 0 (0) | ||
Others | 61 (3.2) | 4 (5.5) | ||
Lauren classification | 0.010a | |||
Intestinal | 659 (34.7) | 14 (19.2) | ||
Diffuse | 1195 (62.9) | 56 (76.7) | ||
Mixed | 47 (2.5) | 3 (4.1) | ||
T stage | 0.058 | |||
pT1 | 155 (8.2) | 0 (0) | ||
pT2 | 493 (25.9) | 17 (23.3) | ||
pT3 | 1047 (55.1) | 46 (63.0) | ||
pT4 | 206 (10.8) | 10 (13.7) | ||
N stage | 0.006 | |||
pN0 | 261 (13.7) | 8 (11) | ||
pN1 | 599 (31.5) | 16 (21.9) | ||
pN2 | 448 (23.6) | 12 (16.4) | ||
pN3 | 593 (31.2) | 37 (50.7) | ||
M stage | 0.396 | |||
pM0 | 1723 (90.6) | 64 (87.7) | ||
pM1 | 178 (9.4) | 9 (12.3) | ||
